Akari Therapeutics ADR (AKTX) Stock Price, Quote & News

Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads in...

Industry: Biotechnology

Sector: Healthcare

Phone: 929 274 7510

Fax: 929 274 7553

Website: www.akaritx.com

Address:

22 Boston Wharf Road, Floor 7, Boston, United States

OfficialStocktwitsUser Feb. 2 at 8:53 PM

$AKTX RSI: 34.75, MACD: -0.0234 Vol: 0.02, MA20: 0.27, MA50: 0.32 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

pc247cz Jan. 30 at 3:47 PM

$AKTX glad to see some life here. The volume is very low, as this current market is not very supportive of this kind of fragile and speculative plays.

0 · Reply

richeey Jan. 30 at 1:58 PM

$AKTX what ever happened to the ticks?

2 · Reply

MTN Jan. 29 at 6:46 PM

$AKTX going to 0. What a pathetic group of folks who accomplished nothing. Could have had a 1B+ company, squandered it.

0 · Reply

suitedandbooted Jan. 26 at 2:19 PM

$AKTX another bio low entry point for a swing ? Watching

0 · Reply

stockscan Jan. 26 at 1:50 PM

$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-files-key-patent-and-unveils-second-adc

0 · Reply

LindaMcrae715 Jan. 26 at 2:36 AM

$AKTX Recent equity offerings and financings have generated fresh capital, including insider participation, to support operations and fund R&D work critical in a capital-intensive biotech…

0 · Reply

LindaMcrae715 Jan. 26 at 2:34 AM

$AKTX Akari appointed a new Head of Business Development for Oncology, bringing deeper industry expertise to help build partnerships and execute its strategy!!

0 · Reply

LindaMcrae715 Jan. 26 at 2:33 AM

$AKTX The company has been participating in investor conferences and webcasts highlighting its ADC platform and long-term path including virtual investor events outlining key investment reasons and pipeline strengths.

0 · Reply

LindaMcrae715 Jan. 26 at 2:32 AM

$AKTX

0 · Reply

Akari Therapeutics Files Key Patent and Unveils Second ADC Program AKTX-102 Targeting CEACAM5 Expressing Solid Tumors

Jan 9, 2026, 9:00 AM EST - 25 days ago

Akari Therapeutics Releases New CEO Corner Segment Highlighting 2025 Progress and Path to Clinical Transition In 2026

Jan 8, 2026, 9:15 AM EST - 26 days ago

Akari Therapeutics to Present at the 2026 Biotech Showcase

Dec 30, 2025, 9:15 AM EST - 5 weeks ago

Akari Therapeutics Issues 2025 End of Year Letter to Shareholders

Dec 23, 2025, 8:30 AM EST - 6 weeks ago

Akari Therapeutics Initiates GMP Manufacturing of AKTX-101 ADC Program to Support Phase 1 First-in-Human Clinical Trial

Dec 18, 2025, 8:30 AM EST - 6 weeks ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Dec 16, 2025, 9:29 AM EST - 7 weeks ago

Akari Therapeutics Announces $5 Million Financing, Including Concurrent Registered Direct Offering and Private Placement Priced At-Market

Dec 9, 2025, 8:40 AM EST - 2 months ago

Akari Therapeutics Highlights Preclinical Data Demonstrating Therapeutic Potential of Lead Candidate, AKTX-101, for Hard-to-Treat K-Ras Mutant Pancreatic Cancer

Dec 4, 2025, 9:00 AM EST - 2 months ago

Akari Therapeutics Provides Corporate Update and Highlights its ADC Payload Innovation Expected to Drive Value in New CEO Corner Segment

Nov 25, 2025, 9:00 AM EST - 2 months ago

Akari Therapeutics Announces Release of the Next CEO Corner Segment

Nov 18, 2025, 7:08 PM EST - 2 months ago

Akari Therapeutics, Plc (AKTX) Shareholder/Analyst Call Transcript

Nov 18, 2025, 8:35 AM EST - 2 months ago

Akari Therapeutics Appoints Biotech Finance Leader, Kameel D. Farag as Interim Chief Financial Officer

Nov 10, 2025, 8:30 AM EST - 3 months ago

Akari Therapeutics Presents Promising Immuno-Oncology Data for its Novel Splicing-Targeted ADC Payload Driving Immune Activation, Both as Single Agent and in Combination with Anti-PD1 Checkpoint Inhibitors

Nov 4, 2025, 9:25 AM EST - 3 months ago

Akari Therapeutics' Accepted Abstract Showcasing its Novel Splicing-Targeted ADC Payload Driving Immune Activation Now Available

Oct 30, 2025, 8:35 AM EDT - 3 months ago

Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

Oct 22, 2025, 9:05 AM EDT - 3 months ago

Akari Therapeutics Announces Launch of CEO Corner Platform

Oct 15, 2025, 8:30 AM EDT - 3 months ago

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

Oct 9, 2025, 8:45 AM EDT - 4 months ago

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Oct 3, 2025, 9:30 AM EDT - 4 months ago

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Sep 24, 2025, 8:45 AM EDT - 4 months ago

Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Sep 17, 2025, 8:45 AM EDT - 4 months ago

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

Sep 10, 2025, 1:44 PM EDT - 5 months ago

Akari Therapeutics, Plc (AKTX) Discusses At Virtual Investor Closing Bell Series Call (Transcript)

Sep 5, 2025, 6:45 AM EDT - 5 months ago

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 5 months ago

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 14, 2025, 9:15 AM EDT - 6 months ago

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 23, 2025, 8:55 AM EDT - 6 months ago

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Jul 22, 2025, 8:45 AM EDT - 7 months ago

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jun 25, 2025, 9:00 AM EDT - 7 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Jun 18, 2025, 8:50 AM EDT - 8 months ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

May 29, 2025, 9:15 AM EDT - 8 months ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 22, 2025, 9:00 AM EDT - 9 months ago

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 19, 2025, 8:00 AM EDT - 9 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP QURE

May 15, 2025, 8:05 AM EDT - 9 months ago

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 1, 2025, 8:45 AM EDT - 9 months ago

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Apr 22, 2025, 9:05 AM EDT - 10 months ago

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Mar 20, 2025, 8:35 AM EDT - 11 months ago

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Mar 3, 2025, 9:00 AM EST - 1 year ago

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Feb 19, 2025, 9:00 AM EST - 1 year ago

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 3, 2025, 8:00 AM EST - 1 year ago

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Dec 18, 2024, 8:51 AM EST - 1 year ago

Akari Therapeutics Announces Key Leadership Appointments

Dec 16, 2024, 9:05 AM EST - 1 year ago

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Nov 14, 2024, 4:15 PM EST - 1 year ago

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Nov 8, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Aug 19, 2024, 4:15 PM EDT - 1 year ago

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

May 16, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

May 1, 2024, 8:01 AM EDT - 1 year ago

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

May 1, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Apr 1, 2024, 6:30 AM EDT - 2 years ago

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

OfficialStocktwitsUser Feb. 2 at 8:53 PM

0 · Reply

pc247cz Jan. 30 at 3:47 PM

$AKTX glad to see some life here. The volume is very low, as this current market is not very supportive of this kind of fragile and speculative plays.

0 · Reply

richeey Jan. 30 at 1:58 PM

$AKTX what ever happened to the ticks?

2 · Reply

MTN Jan. 29 at 6:46 PM

$AKTX going to 0. What a pathetic group of folks who accomplished nothing. Could have had a 1B+ company, squandered it.

0 · Reply

suitedandbooted Jan. 26 at 2:19 PM

$AKTX another bio low entry point for a swing ? Watching

0 · Reply

stockscan Jan. 26 at 1:50 PM

$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-files-key-patent-and-unveils-second-adc

0 · Reply

LindaMcrae715 Jan. 26 at 2:36 AM

$AKTX Recent equity offerings and financings have generated fresh capital, including insider participation, to support operations and fund R&D work critical in a capital-intensive biotech…

0 · Reply

LindaMcrae715 Jan. 26 at 2:34 AM

$AKTX Akari appointed a new Head of Business Development for Oncology, bringing deeper industry expertise to help build partnerships and execute its strategy!!

0 · Reply

LindaMcrae715 Jan. 26 at 2:33 AM

0 · Reply

LindaMcrae715 Jan. 26 at 2:32 AM

$AKTX

0 · Reply

Milos89 Jan. 25 at 2:00 AM

$AKTX 0,4$ next

0 · Reply

pc247cz Jan. 23 at 3:00 PM

$AKTX I’m surprised there’s no R/S agenda item at the General Meeting. That feels bullish to me. Any further dilution should already be priced in, though March will be interesting. Hopefully, I’ll be out by then.

0 · Reply

Love_To_Learn Jan. 23 at 12:27 PM

$AKTS sorry was for $AKTX **************

0 · Reply

Kesiya Jan. 22 at 8:45 AM

📈 Top 10 Premarket Stocks to Watch | Jan 22, 2026 Upd. 1️⃣ $AREB Float/OS: 7.95M / 7.96M | Fee 75.33% | Avail 550K ➡️ Extremely tight float + very high borrow fee. Strong volatility setup. 2️⃣ IOBT Float/OS: 33.45M / 71.95M | Fee 4.96% | Avail 2.3M ➡️ Company announced review of strategic alternatives (M&A / asset sale). 3️⃣ $AKTX Float/OS: 33.76M / 48.26M | Fee 8.82% | Avail 5.7M ➡️ Oncology biotech with ADC platform. 2026 milestones in focus. 4️⃣ $AURE Float/OS: 311.02M / 356.69M | Fee 2.69% | Avail 350K 5️⃣ ATPC Float & OS:48.63M / 50.03M Fee 22.57% Avail 150000 6️⃣ $ONFO Float/OS: 3.57M / 5.87M | Fee 11.60% | Avail 450K 7️⃣ CABA Float/OS: 99.67M / 102.27M | Fee 0.41% | Avail 1.7M 8️⃣ EDBL Float/OS: 5.13M / 5.13M | Fee 25.75% | Avail 250K 9️⃣ $SMTK Float/OS: 4.7M / 6.13M | Fee 25.37% | Avail 150K 🔟 SMXT Float/OS: 39.28M / 54.30M | Fee 12.03% | Avail 750K ⚠️ High‑risk, high‑volatility premarket momentum trades. Not financial advice.

0 · Reply

Kesiya Jan. 22 at 6:21 AM

📈 Top 5 Premarket Stocks to Watch | Jan 22, 2026 1️⃣ $AREB Float/OS: 7.95M / 7.96M | Fee 75.33% | Avail 550K ➡️ Extremely tight float + very high borrow fee. Strong volatility setup. 2️⃣ $IOBT Float/OS: 33.45M / 71.95M | Fee 4.96% | Avail 2.3M ➡️ Company announced review of strategic alternatives (M&A / asset sale). 3️⃣ $AKTX Float/OS: 33.76M / 48.26M | Fee 8.82% | Avail 5.7M ➡️ Oncology biotech with ADC platform. 2026 milestones in focus. 4️⃣ $AURE Float/OS: 311.02M / 356.69M | Fee 2.69% | Avail 350K ➡️ AI & fintech play. Recent ATM filing = high volume & momentum watch. 5️⃣ $CUE Float/OS: 127.84M / 133.36M | Fee 0.82% | Avail 5.7M ➡️ Immunotherapy biotech. Recently raised capital, watching for base & bounce. ⚠️ High‑risk, high‑volatility momentum names. Not financial advice. Trade with a plan. #Premarket #Stocktwits #Momentum #SmallCaps #Biotech

0 · Reply

pc247cz Jan. 21 at 10:38 AM

Which one will explode first ? $RANI or $AKTX ?

0 · Reply

pc247cz Jan. 14 at 1:23 PM

$AKTX Still believe that first quarter will be great for AKTX. Waiting for volume and massive price increase that will follow. GLTTA.

1 · Reply

SuperGreenToday Jan. 9 at 4:17 PM

$AKTX

0 · Reply

stockscan Jan. 8 at 2:19 PM

$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-present-2026-biotech-showcase

0 · Reply

pc247cz Jan. 7 at 4:25 PM

$AKTX Volume has dried up—AKTX is at a crossroads. My biggest position. Very speculative.

0 · Reply

notreload_ai Jan. 5 at 3:26 PM

$LMRI $AKTX $BMNR $SBET $VTVT $CPRI -- THE WSJ

0 · Reply

JSP_Dilution_Player Jan. 5 at 2:33 PM

$AKTX got $1 target today

0 · Reply

Market Cap	8.39M
Revenue (ttm)	0.00
Net Income (ttm)	-19.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.03

Volume	104,800
Avg Vol	1,272,820
Day's Range	N/A - N/A
Shares Out	35.74M
Stochastic %K	19%
Beta	0.27
Analysts	Strong Sell
Price Target	$2.90